Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 9/2018

01-09-2018 | Original Article

Heart rate variability for rapid risk stratification of emergency patients with malignant disease

Authors: K. Boehm, M. Duckheim, L. Mizera, P. Groga-Bada, N. Malek, F. Kreth, M. Gawaz, C. S. Zuern, C. Eick

Published in: Supportive Care in Cancer | Issue 9/2018

Login to get access

Abstract

Introduction

Neoplasms are the second most common diseases in western countries. Many patients with malignant diseases repeatedly present themselves in the emergency department (ED). Due to limited capacities, appropriate risk stratification strategies for cancer patients have to be developed. This study assesses if deceleration capacity (DC) of heart rate as a parameter of heart rate variability predicts mortality in emergency patients with malignant diseases.

Methods

Prospectively, 140 adults with different entities of malignant diseases who presented in the medical ED were included. Primary and secondary endpoints were intrahospital mortality and mortality within 180 days, respectively. We calculated DC from short-term ECG readings of the surveillance monitors. Additionally, the Modified Early Warning Score (MEWS) and laboratory parameters such as white blood cells (WBC), lactate dehydrogenase, serum hemoglobin, and serum creatinine were determined.

Results

The median age of the patients was 65 ± 14 years. 19.3% of the patients died within the hospital stay and 57.9% died within 180 days. DC and WBC were independent predictors of intrahospital death reaching a hazard ratio (HR) of 0.79 (95% confidence interval (CI) 0.63–0.993, p = 0.043) and of 1.00 (95% CI 1.00–1.00, p = 0.003), respectively. DC and serum creatinine independently predicted death within 180 days (HR 0.90, 95% CI 0.82–0.98, p = 0.023 and HR 1.41, 95% CI 1.05–1.90, p = 0.018, respectively).

Conclusion

Deceleration capacity of heart rate is suitable for rapid risk assessment of emergency patients with malignant diseases.
Literature
1.
Van Galen LS, Dijkstra CC, Ludikhuize J, Kramer MH, Nanayakkara PW (2016) A protocolised once a day Modified Early Warning Score (MEWS) measurement is an appropriate screening tool for major adverse events in a general hospital population. PLoS One 11(8):e0160811CrossRefPubMedPubMedCentral
2.
Löllgen H (1999) Herzfrequenzvariabilität. Dt Ärztebl 96:A-2029–A-2032 [Heft 31–32]
3.
Harris PR, Stein PK, Fung GL, Drew BJ (2014) Heart rate variability measured early in patients with evolving acute coronary syndrome and 1-year outcomes of rehospitalization and mortality. Vasc Health Risk Manag 10:451–464CrossRefPubMedPubMedCentral
4.
Ong ME, Goh K, Fook-Chong S, Haaland B, Wai KL, Koh ZX et al (2013) Heart rate variability risk score for prediction of acute cardiac complications in ED patients with chest pain. Am J Emerg Med 31(8):1201–1207CrossRefPubMed
5.
Bauer A, Kantelhardt JW, Barthel P, Schneider R, Mäkikallio T, Ulm K, Hnatkova K, Schömig A, Huikuri H, Bunde A, Malik M, Schmidt G (2006) Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet 367:1674–1681CrossRefPubMed
6.
Zuern CS, Rizas KD, Eick C, Vogtt MI, Bigalke B, Gawaz M, Bauer A (2014) Severe autonomic failure as a predictor of mortality in aortic valve stenosis. Int J Cardiol 176(3):782–787CrossRefPubMed
7.
Poreba M, Poreba R, Gac P, Usnarska-Zubkiewicz L, Pilecki W, Piotrowicz E et al (2014) Heart rate variability and heart rate turbulence in patients with hematologic malignancies subjected to high-dose chemotherapy in the course of hematopoietic stem cell transplantation. Ann Noninvasive Electrocardiol 19(2):157–165CrossRefPubMed
8.
Ahmad S, Ramsay T, Huebsch L, Flanagan S, McDiarmid S, Batkin I, McIntyre L, Sundaresan SR, Maziak DE, Shamji FM, Hebert P, Fergusson D, Tinmouth A, Seely AJE (2009) Continuous multi-parameter heart rate variability analysis heralds onset of sepsis in adults. PLoS One 4(8):e6642CrossRefPubMedPubMedCentral
9.
Chen WL, Chen JH, Huang CC, Kuo CD, Huang CI, Lee LS (2008) Heart rate variability measures as predictors of in-hospital mortality in ED patients with sepsis. Am J Emerg Med 26(4):395–401CrossRefPubMed
10.
Guo Y, Koshy S, Hui D, Palmer JL, Shin K, Bozkurt M, Wamique Yusuf S (2015) Prognostic value of heart rate variability in patients with cancer. J Clin Neurophysiol 32(6):516–520CrossRefPubMedPubMedCentral
11.
Zhou X, Ma Z, Zhang L, Zhou S, Wang J, Wang B, Fu W (2016) Heart rate variability in the prediction of survival in patients with cancer: a systematic review and meta-analysis. J Psychosom Res 89:20–25CrossRefPubMed
12.
De Couck M, Gidron Y (2013) Norms of vagal nerve activity, indexed by heart rate variability, in cancer patients. Cancer Epidemiol 37(5):737–741CrossRefPubMed
13.
Arab C, Dias DP, Barbosa RT, Carvalho TD, Valenti VE, Crocetta TB et al (2016) Heart rate variability measure in breast cancer patients and survivors: a systematic review. Psychoneuroendocrinology 68:57–68CrossRefPubMed
14.
Guo Y, Palmer JL, Strasser F, Yusuf SW, Bruera E (2013) Heart rate variability as a measure of autonomic dysfunction in men with advanced cancer. Eur J Cancer Care (Engl) 22(5):612–616CrossRef
15.
Chiang JK, Kuo TB, Fu CH, Koo M (2013) Predicting 7-day survival using heart rate variability in hospice patients with non-lung cancers. PLoS One 8(7):e69482CrossRefPubMedPubMedCentral
16.
Wang YM, Wu HT, Huang EY, Kou YR, Hseu SS (2013) Heart rate variability is associated with survival in patients with brain metastasis: a preliminary report. Biomed Res Int 2013:503421PubMedPubMedCentral
17.
Statistisches Bundesamt. Todesursachen nach Krankheitsarten 2014. Wiesbaden 2015
18.
Ferrat E, Paillaud E, Laurent M, Le Thuaut A, Caillet P, Tournigand C et al (2015) Predictors of 1-year mortality in a prospective cohort of elderly patients with cancer. J Gerontol A Biol Sci Med Sci 70(9):1148–1155CrossRefPubMed
19.
Lian J, Wang L, Muessig D (2011) A simple method to detect atrial fibrillation using RR intervals. Am J Cardiol 107(10):1494–1497CrossRefPubMed
20.
Eick C, Rizas KD, Meyer-Zurn CS, Groga-Bada P, Hamm W, Kreth F et al (2015) Autonomic nervous system activity as risk predictor in the medical emergency department: a prospective cohort study. Crit Care Med 43(5):1079–1086CrossRefPubMed
21.
Eick C, Rizas KD, Zuern CS, Bauer A (2014) Automated assessment of cardiac autonomic function by means of deceleration capacity from noisy, nonstationary ECG signals: validation study. Ann Noninvasive Electrocardiol: Off J Int Soc Holter Noninvasive Electrocardiol Inc 19:122–128CrossRef
22.
Bauer A, Kantelhardt JW, Bunde A, Barthel P, Schneider R, Malik M, Schmidt G (2006) Phase-rectified signal averaging detects quasi-periodicities in non-stationary data. Phys A Stat Mech Appl 364:423–434CrossRef
23.
Bauer A, Kantelhardt JW, Barthel P, Schneider R, Makikallio T, Ulm K et al (2006) Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet 367(9523):1674–1681CrossRefPubMed
24.
Subbe CP, Kruger M, Rutherford P, Gemmel L (2001) Validation of a modified Early Warning Score in medical admissions. QJM 94(10):521–526CrossRefPubMed
25.
Duckheim M, Klee K, Gotz N, Helle P, Groga-Bada P, Mizera L et al (2017) Deceleration capacity as a risk predictor in patients presenting to the emergency department with syncope: a prospective exploratory pilot study. Medicine (Baltimore) 96(49):e8605CrossRef
26.
Duckheim M, Bensch C, Kittlitz L, Gotz N, Klee K, Groga-Bada P et al (2017) Deceleration capacity of heart rate predicts 1-year mortality of patients undergoing transcatheter aortic valve implantation. Clin Cardiol 40(10):919–924CrossRefPubMed
27.
Zentrum für Krebsregisterdaten. Robert Koch Institut. Verbreitung von Krebserkrankungen in Deutschland. Krebs Gesamt- Ergebnisse zur Prävalenz. S. 157
28.
Kostakou E, Rovina N, Kyriakopoulou M, Koulouris NG, Koutsoukou A (2014) Critically ill cancer patient in intensive care unit: issues that arise. J Crit Care 29(5):817–822CrossRefPubMed
29.
De Couck M, van Brummelen D, Schallier D, De Greve J, Gidron Y (2013) The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients. Oncol Rep 30(5):2435–2441CrossRefPubMed
30.
Gidron Y, De Couck M, De Greve J (2014) If you have an active vagus nerve, cancer stage may no longer be important. J Biol Regul Homeost Agents 28(2):195–201PubMed
31.
Adams SC, Schondorf R, Benoit J, Kilgour RD (2015) Impact of cancer and chemotherapy on autonomic nervous system function and cardiovascular reactivity in young adults with cancer: a case-controlled feasibility study. BMC Cancer 15:414CrossRefPubMedPubMedCentral
32.
Walsh D, Nelson KA (2002) Autonomic nervous system dysfunction in advanced cancer. Support Care Cancer 10(7):523–528CrossRefPubMed
33.
Niederer D, Vogt L, Thiel C, Schmidt K, Bernhorster M, Lungwitz A et al (2013) Exercise effects on HRV in cancer patients. Int J Sports Med 34(1):68–73PubMed
34.
Shankar A, Wang JJ, Rochtchina E, Yu MC, Kefford R, Mitchell P (2006) Association between circulating white blood cell count and cancer mortality: a population-based cohort study. Arch Intern Med 166(2):188–194CrossRefPubMed
35.
Na SY, Sung JY, Chang JH, Kim S, Lee HH, Park YH, Chung W, Oh KH, Jung JY (2011) Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol 33(2):121–130CrossRefPubMed
36.
Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, Walldius G, Jungner I, Ng T, van Hemelrijck M (2015) Serum lactate dehydrogenase and survival following cancer diagnosis. Br J Cancer 113(9):1389–1396CrossRefPubMedPubMedCentral
37.
Lardaro T, Self WH, Barrett TW (2015) Thirty-day mortality in ED patients with new onset atrial fibrillation and actively treated cancer. Am J Emerg Med 33(10):1483–1488CrossRefPubMedPubMedCentral
Metadata
Title
Heart rate variability for rapid risk stratification of emergency patients with malignant disease
Authors
K. Boehm
M. Duckheim
L. Mizera
P. Groga-Bada
N. Malek
F. Kreth
M. Gawaz
C. S. Zuern
C. Eick
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4144-y

Other articles of this Issue 9/2018

Supportive Care in Cancer 9/2018 Go to the issue

Original Article

Multidrug-resistant bacterial microorganisms (MDRO) in end-of-life care: development of recommendations for hospitalized patients using a mixed-methods approach

Original Article

A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy

Original Article

The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial

Original Article

Palliative sedation in advanced cancer patients hospitalized in a specialized palliative care unit

Original Article

The impact of dietary regimen compliance on outcomes for HNSCC patients treated with radiation therapy

Original Article

Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits